OCULAR THERAPEUTIX, INC Operating Lease Cost
OCULAR THERAPEUTIX, INC (OCUL) reported Operating Lease Cost of $3.39 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC operating lease, cost for the quarter ending 2019-12-31 was $446.00K.
- OCULAR THERAPEUTIX, INC operating lease, cost for the quarter ending 2019-09-30 was $591.00K.
- OCULAR THERAPEUTIX, INC operating lease, cost for the quarter ending 2019-06-30 was $591.00K.
- OCULAR THERAPEUTIX, INC operating lease, cost for the quarter ending 2019-03-31 was $442.00K.
- OCULAR THERAPEUTIX, INC operating lease, cost for fiscal 2025 was $3.39M, a 12.06% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC operating lease, cost for fiscal 2024 was $3.03M, a 13.67% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC operating lease, cost for fiscal 2023 was $2.66M, a 12.41% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC operating lease, cost for fiscal 2022 was $2.37M, a 4.55% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.39M 10-K · filed 2026-02-05 | ||||
| 2024-12-31 | $3.03M 10-K · filed 2026-02-05 | ||||
| 2023-12-31 | $2.66M 10-K · filed 2026-02-05 | ||||
| 2022-12-31 | $2.37M 10-K · filed 2025-03-03 | ||||
| 2021-12-31 | $2.48M 10-K · filed 2024-03-11 | ||||
| 2020-12-31 | $2.42M 10-K · filed 2023-03-06 | ||||
| 2019-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.04M derived: sum of 2 quarters · filed 2022-02-28 | $1.63M derived: sum of 3 quarters · filed 2022-02-28 | $2.07M 10-K · filed 2022-02-28 | $2.21M 10-K · filed 2020-03-12 |
| 2019-09-30 | $591.00K 10-Q · filed 2019-11-12 | $1.18M derived: sum of 2 quarters · filed 2019-11-12 | $1.62M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $591.00K 10-Q · filed 2019-08-07 | $1.03M 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $442.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |